Compounds > piperidolate
Page last updated: 2024-12-05

piperidolate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Piperidolate is an anticholinergic drug that was initially developed for the treatment of gastrointestinal disorders, but it was later found to have other potential therapeutic applications. It acts as a muscarinic acetylcholine receptor antagonist, blocking the action of acetylcholine at these receptors. Piperidolate has been studied for its potential to treat a variety of conditions, including Parkinson's disease, Alzheimer's disease, and even certain types of cancer. The compound's synthesis involves a multi-step process that starts with the reaction of 4-piperidone with an appropriate ester. Further research is necessary to fully understand the pharmacological profile and potential therapeutic applications of piperidolate.'

piperidolate: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4839
CHEMBL ID1623992
CHEBI ID91986
SCHEMBL ID249131
MeSH IDM0055684

Synonyms (87)

Synonym
BRD-A97479839-003-05-9
benzeneacetic acid, .alpha.-phenyl-, 1-ethyl-3-piperidinyl ester
KBIO1_000112
DIVK1C_000112
piperidolatum [inn-latin]
piperidolato [inn-spanish]
brn 0031110
piperidolate [inn:ban]
jb 305
3-piperidinol, 1-ethyl-, diphenylacetate (ester)
diphenylacetic acid, 1-ethyl-3-piperidyl ester
1-ethyl-3-piperidyl diphenylacetate
benzeneacetic acid, alpha-phenyl-, 1-ethyl-3-piperidinyl ester
einecs 201-449-7
acetic acid, diphenyl-, 1-ethyl-3-piperidyl ester
n-ethyl-3-piperidyl diphenylacetate
an 1087
SPECTRUM_001383
BPBIO1_001112
NCGC00178395-02
NCGC00178395-01
PRESTWICK2_001055
BSPBIO_002908
SPECTRUM5_001067
IDI1_000112
piperidolate
(1-ethyl-3-piperidyl) 2,2-diphenylacetate
benzeneacetic acid,.alpha.-phenyl-, 1-ethyl-3-piperidinyl ester
dactil
AB00053633
BSPBIO_001010
KBIO2_001863
KBIO3_002408
KBIO2_004431
KBIO2_006999
KBIOGR_001034
KBIOSS_001863
PRESTWICK1_001055
SPECTRUM4_000737
SPECTRUM3_001524
NINDS_000112
PRESTWICK0_001055
SPBIO_001086
SPECTRUM2_001073
SPBIO_002935
PRESTWICK3_001055
L001277
82-98-4
piperidolate (inn)
D08382
(1-ethylpiperidin-3-yl) 2,2-diphenylacetate
bdbm82378
nsc_4839
cas_82-98-4
AKOS016013077
piperidolato
rjo31255v9 ,
piperidolatum
unii-rjo31255v9
1087 a.n.
1087-a.n.
jb-305
CHEMBL1623992
piperidolate [inn]
piperidolate [mi]
piperidolate [who-dd]
SCHEMBL249131
CS-4447
DTXSID7048164
KTHVBAZBLKXIHZ-UHFFFAOYSA-N
3-piperidinol, 1-ethyl-, diphenylacetate
1-ethyl-3-piperidinyl diphenylacetate #
1-ethylpiperidin-3-yl 2,2-diphenylacetate ,
HY-B0962A
AB00053633_07
mfcd00242588
2,2-diphenylacetic acid (1-ethyl-3-piperidinyl) ester
CHEBI:91986
SBI-0051738.P002
DB13351
Q7197354
BRD-A97479839-003-08-3
BCP31766
1087 a.n.; brn 0031110; dactil; jb 305; piperidolatum
MS-24807
EX-A3194
AC-35671
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.02 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
cardiovascular agents
Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.		2.3420
ConditionIndicatedRelationship StrengthStudiesTrials
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Hypothermia, Accidental
[description not available]		02.3420
Hypothermia
Lower than normal body temperature, especially in warm-blooded animals.		02.3420
Ventricular Fibrillation
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.		07.3420
Cardiac Conduction Defect
[description not available]		01.9310
Arrhythmia
[description not available]		01.9310
Brugada ECG Pattern
[description not available]		01.9310
Arrhythmias, Cardiac
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.		01.9310
Brugada Syndrome
An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.		01.9310